Actaea Spicata Root Anagallis Arvensis Argemone Me
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Actaea Spicata Root Anagallis Arvensis Argemone Me
- Multi-Ingredient Homeopathic Preparation: Insufficient Data for Drug Repurposing Evaluation
Multi-Ingredient Homeopathic Preparation: Insufficient Data for Drug Repurposing Evaluation
One-Sentence Summary
This candidate consists of 12 botanical, biological, and mineral homeopathic ingredients (including Actaea spicata root, Hyoscyamus niger, potassium dichromate, and roasted sea sponge), with no approved indications, no US market authorization, and no DrugBank ID on record. The TxGNN model generated no predicted indications for this candidate, meaning no drug repurposing direction can currently be proposed. Without a DrugBank identifier or structured pharmacological profile, the pipeline was unable to map this compound to the knowledge graph.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None documented |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only (no prediction available) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction was generated for this candidate. The following explains why repurposing analysis cannot proceed at this time.
This entry represents a complex multi-ingredient preparation composed of 12 components drawn from homeopathic pharmacopoeia, including plant extracts (Actaea spicata, Anagallis arvensis, Argemone mexicana, Hyoscyamus niger, Senna leaf), a biological agent (Candida albicans), an animal-derived venom (Heloderma horridum venom), mineral salts (potassium dichromate, potassium iodide, potassium nitrate, dibasic potassium phosphate), and a roasted marine organism (Spongia officinalis skeleton).
Individually, several components have known pharmacological activity at standard doses — for example, hyoscine alkaloids from Hyoscyamus niger are anticholinergic, sennosides from senna are laxative, and potassium iodide has established use in thyroid conditions. However, as a combined homeopathic formulation, the preparation lacks a unified mechanism of action (MOA), and no DrugBank entity could be mapped to the multi-ingredient string as a whole.
Because TxGNN’s knowledge graph operates on single drug entities with DrugBank IDs and defined molecular targets, this preparation falls outside the scope of the current prediction pipeline. A meaningful repurposing evaluation would require decomposing the formulation and analyzing each pharmacologically active component independently.
Clinical Trial Evidence
Currently no related clinical trials registered for this multi-ingredient preparation as a combined entity.
Literature Evidence
Currently no related literature available for this multi-ingredient preparation as a combined entity.
US Market Information
This preparation has no US NDA or market authorization on record. The TFDA query returned 0 results, confirming it is not currently marketed or licensed.
Safety Considerations
Please refer to the package insert for safety information.
Note: No safety data (warnings, contraindications, or drug-drug interactions) was retrievable for this preparation. Several individual components carry known safety concerns at pharmacological doses — for example, Hyoscyamus niger contains anticholinergic alkaloids, Argemone mexicana contains toxic isoquinoline alkaloids, and potassium dichromate is classified as a carcinogen and nephrotoxin. Any clinical use or investigation would require component-level toxicology review.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline was unable to generate any repurposing predictions because this multi-ingredient homeopathic preparation cannot be mapped to a single DrugBank entity or knowledge graph node. Without a structured pharmacological profile, the evidence base is insufficient to support a repurposing hypothesis.
To proceed, the following is needed:
- DrugBank ID or structured entity mapping: Determine whether any individual component (e.g., hyoscyamine from Hyoscyamus niger, sennosides from senna) should be analysed independently as a repurposing candidate
- Regulatory clarification: Confirm whether this preparation is intended as a homeopathic product (OTC, non-prescription) or as a drug requiring full regulatory dossier
- MOA documentation: For each pharmacologically active component, retrieve mechanism of action data from DrugBank or primary literature
- Component-level TxGNN run: Decompose the formulation and submit each active ingredient separately through the repurposing pipeline
- Safety review: Conduct component-level toxicology assessment, particularly for Argemone mexicana (argemone oil toxicity), potassium dichromate (Cr⁶⁺ carcinogenicity), and Heloderma horridum venom (exendin-class peptides)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.